ENLV
EnlivexBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
RMAT designation strengthens the regulatory path for Allocetra, while active Phase 2b execution and potential Q2 2027 topline data provide the clearest rerating route.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Nasdaq minimum-bid-price compliance deadline and potential corporate-action risk.
Momentum
87
Value
44
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.00 · Bear $2.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $300.00
Why
Momentum87 · Δ7d -
Value44 · Δ7d -0.1
Sentiment49 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
87
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
49
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 87.4 / Value 44.3 / Sentiment 49.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$78.77M
Beta
1.61
Shares Out
16.83M
P/E (TTM) · Derived
0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.57
Rev YoY
-
EPS YoY
-11881.8%
Gross Margin
-
Op Margin
-
Net Debt
-$5.23M
Current Ratio
193.24
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology